-transparent.png){kind=logo}
Probucol, which decreases cholesterol levels and has antioxidant properties, was administered orally to patients with familial combined hyperlipidemia and high plasma lipoprotein(a) [Lp(a)] levels. The drug had no effect on Lp(a) concentrations after 4 weeks, but was found to be distributed in both Lp(a) and low-density lipoprotein (LDL). Before treatment, in each case LDL and Lp(a) isolated from the same individual were readily oxidized by copper, resulting in increased electrophoretic mobility and enhanced uptake and degradation by macrophages of both lipoproteins. After probucol treatment, both lipoproteins acquired resistance to in vitro oxidation by copper. Furthermore, probucol prevented their enhanced uptake and degradation by the macrophages. It is surmised that oxidized Lp(a) may carry an atherogenic potential that could be opposed by probucol administration.
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
February 1986,
The Journal of clinical investigation,
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
January 1997,
Free radical biology & medicine,
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
April 1997,
Heart (British Cardiac Society),
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
January 1999,
Life sciences,
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
December 2001,
The British journal of nutrition,
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
February 1991,
The Journal of clinical investigation,
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
August 2011,
DNA repair,
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
December 1993,
Atherosclerosis,
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
May 1992,
The Journal of clinical investigation,
M Naruszewicz, and
E Selinger, and
R Dufour, and
J Davignon
January 2015,
PloS one,
